VIDEO LINK - COMBI-BIO investigators introduce their project
Image 1
Image 2
Image 3
Video showing COMBI-BIO investigators as they introduce their project which brought together world-leading expertise in cardiology, biostatistics, bioinformatics, metabolic phenotyping and...
VIDEO LINK - COMBI-BIO investigators introduce their project
The EU funded COMBI-BIO project aims to develop new combinational biomarkers for subclinical atherosclerosis to aid early detection of coronary heart and cardiovascular disease.
Image 1
The combinational biomarkers can aid early detection and personalised patient treatment for people at risk.
Image 2
The COMBI-BIO project brings together experts in the field from institutions across the globe.
Image 3

Our Research

COMBI-BIO is a consortium, funded by the EU's research framework programme, that brings together leading groups in systems medicine, biomarker discovery, epidemiology, critical evaluation and development of coronary heart and cardiovascular disease risk functions, and computational medicine.

About Atherosclerosis

Atherosclerosis is a systemic, chronic disease of the arteries starting as early as childhood and adolescence or young adulthood. Untreated, atherosclerosis can lead to heart disease and stroke, the leading causes of death and disability world-wide.

Our Partners

The collaborative activities of the COMBI-BIO research has been divided amongst six of the world's leading organisations, each with exstensive experience and expertise.